Cadila Healthcare

Cadila Healthcare Limited (also known as

Zydus Cadila) is an Indian pharmaceutical
company headquartered in Ahmedabad,
Gujarat, India,[3] with revenues of ₹7,104.30
crore (US$1.0 billion) in 2019.[4] It is a
manufacturer of generic drugs.[5]
 Cadila Healthcare Limited

Type Public

Traded as BSE: 532321
NSE: CADILAHC
Industry Pharmaceuticals

Founded 1952

Founder Ramanbhai Patel

Headquarters Ahmedabad, Gujarat,

India
Key people Pankaj R. Patel,
Chairman, Sharvil P.
Patel, Managing
Director
Revenue ₹7,104.30 crore
(US$1.0 billion)
[1] (2019)

Net income ₹1,602.10 crore

(US$220 million)
[2] (2019)

Number of 13180 (2015)

employees

Website www.zyduscadila
.com

History
Cadila was founded in 1952 by Ramanbhai
Patel (1925–2001), formerly a lecturer in
the L.M. College of Pharmacy, and his
business partner Indravadan Modi. It
evolved over the next four decades into an
established pharmaceutical company.

In 1995 the Patel and Modi families split;

the Modi family's share was moved into a
new company called Cadila
Pharmaceuticals Ltd., and Cadila
Healthcare Ltd became the Patel family's
holding company. Cadila Healthcare had
its initial public offering on the Bombay
Stock Exchange in 2000 as stock code
532321.

In 2015 the company acquired another

Indian pharmaceutical company called
German Remedies. On 25 June 2007, the
company acquired Química e
Farmacêutica Nikkho do Brasil Ltda
(Nikkho) as part of Zydus Healthcare
Brasil Ltda.[6]

In 2010, Cadila Healthcare received a

Wellcome Trust Award under the "R&D for
Affordable Healthcare in India" initiative.

In 2014, Cadila Healthcare launched the

world's first adalimumab biosimilar under
the brand name Exemptia at one-fifth the
originator's price.[7] Zydus Cadila
Healthcare has also launched its first
research based drug molecule Saroglitazar
in treatment of Diabetic Dyslipidemia
under brand name "Lipaglyn". SoviHep is
the first sofosbuvir brand launched in India
by Zydus in year 2015.[5]

In 2019, injectable ketorolac tromethamine

manufactured by Zydus (Cadila
Healthcare) was recalled due to microbial
growth.

In 2020, Zydus Cadila's drug Desidustat

received approval by the USFDA to initiate
clinical trials on cancer patients. [8]

Products
From nine pharmaceutical production
operations in India as well as a Zydus
Cadila develops and manufactures a large
range of pharmaceuticals as well as
diagnostics, herbal products, skin care
products and other OTC products. Starting
from late 2015, having concluded a
voluntary license agreement with Gilead,
the company also produces the generics
for hepatitis C treatment (i.e. sofosbuvir,
distributed under the brand name
SoviHep).[9]

The company makes active

pharmaceutical ingredients at three sites
in India, Ankleshwar plants, Vadodara
plant, and Patalganga plant.
COVID-19 vaccine
development
In Februaray 2020, in a press release, the
company announced the launch of
developing a potential COVID-19 DNA
based vaccine from a live attenuated
recombinant measles virus vectored
vaccine to combat the virus.[10] In July
2020, the company got permission to
conduct human trials of the
developmental COVID-19 vaccine named
ZyCoV-D, from the Drugs Controller
General of India (DCGI), Government of
India.[11][12][13]
Cadila is also among the several Indian
pharma companies that received the
licensing agreements from the Gilead
Sciences to produce remdesivir[14]

Corporate control
Zydus Cadila's major shareholder remains
the Patel family. Pankaj Patel (born 1951),
son of the founder, is the chairman of the
company. In 2004, Pankaj Patel was
included in Forbes' annual list of India's
richest people. As of 2020, Forbes
estimates Patel's net worth at US $3.9
billion, making him India's 46th richest
person.[15]
References
1. "Cadila Healthcare Profit and Loss
Reports - The Economic Times" .
economictimes.indiatimes.com.
Retrieved 15 June 2020.
2. "Cadila Healthcare Profit and Loss
Reports - The Economic Times" .
economictimes.indiatimes.com.
Retrieved 15 June 2020.
3. "A Complete Overview on Cadila
Healthcare, a growing and popular
company in India" .
business.mapsofindia.com. 21 June
2011. Retrieved 4 February 2009.
4. "Cadila Healthcare Profit and Loss
Reports - The Economic Times" .
economictimes.indiatimes.com.
Retrieved 15 June 2020.
5. "Zydus launches SoviHep - the
breakthrough therapy for Hepatitis C in
alliance with Gilead Sciences" . The
Hindu Business Line. 17 March 2015.
Retrieved 29 December 2017.
. Company Overview of Química e
Farmacêutica Nikkho do Brasil Ltda
Bloomberg
7. Zydus Cadila launches biosimilar of
AbbVie's Humira in India The
Economic Times 9 December 2014
 . Zydus Cadila Desidustat Gets USFDA
Nod To Initiate Clinical Trials On
Cancer Patients The Times Of India
23 July 2020
9. "Hepatitis C treatment in India for less
than $1000" . hep-c-news.com. Hep C
News. 11 July 2016. Archived from the
original on 16 September 2016.
10. "Zydus Cadila launches a fast tracked
programme to develop vaccine for the
novel coronavirus, 2019-nCoV (COVID-
19)" (PDF). www.zyduscadila.com.
Zydus Cadila. Retrieved 7 August
2020.
11. "Potential COVID-19 vaccine by Zydus
Cadila gets DCGI nod for human
clinical trials" . The Hindu. 3 July 2020.
12. "Zydus Cadila begins human clinical
trials of COVID-19 vaccine candidate -
ET HealthWorld" . ETHealthworld.com.
13. "Zydus Cadila's COVID-19 Vaccine
Candidate Found Safe in Early-Stage
Human Trial" . The New York Times. 5
August 2020.
14. Umarji, Vinay (12 June 2020). "Gilead
finds fourth partner for manufacture of
Remdesivir in Zydus Cadila" . Business
Standard India.
 15. "Pankaj Patel" . Forbes. Retrieved
15 June 2020.

External links
Official website

Retrieved from
"https://en.wikipedia.org/w/index.php?
title=Cadila_Healthcare&oldid=975052469"

Last edited 17 days ago by Prolix

Content is available under CC BY-SA 3.0 unless

otherwise noted.